Envestnet Asset Management Inc. Sells 336 Shares of Becton Dickinson and Co (BDX)

Envestnet Asset Management Inc. reduced its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 0.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,372 shares of the medical instruments supplier’s stock after selling 336 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Becton Dickinson and were worth $19,130,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Legacy Advisors LLC raised its position in Becton Dickinson and by 7,000.0% during the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 490 shares in the last quarter. Amica Retiree Medical Trust grew its holdings in Becton Dickinson and by 325.0% in the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after purchasing an additional 390 shares during the period. Almanack Investment Partners LLC. acquired a new stake in Becton Dickinson and in the fourth quarter valued at approximately $109,000. FTB Advisors Inc. grew its holdings in Becton Dickinson and by 114.2% in the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 290 shares during the period. Finally, Advisors Preferred LLC acquired a new stake in Becton Dickinson and in the fourth quarter valued at approximately $126,000. Institutional investors own 83.35% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of Becton Dickinson and Co (BDX) opened at $210.60 on Monday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93. The stock has a market capitalization of $56,070.57, a P/E ratio of 160.76, a PEG ratio of 1.53 and a beta of 1.18. Becton Dickinson and Co has a 12 month low of $175.66 and a 12 month high of $248.39.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.41 by $0.07. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The business’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.33 earnings per share. research analysts predict that Becton Dickinson and Co will post 10.94 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.42%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 229.01%.

Several brokerages have commented on BDX. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price objective on the stock in a report on Friday, January 19th. Bank of America reissued a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a report on Friday, January 19th. Piper Jaffray Companies reissued an “overweight” rating and issued a $260.00 price objective (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Morgan Stanley raised their price objective on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Finally, KeyCorp began coverage on Becton Dickinson and in a report on Friday, January 5th. They issued an “overweight” rating and a $260.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $238.00.

In other news, EVP James W. Borzi sold 4,048 shares of Becton Dickinson and stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $224.98, for a total value of $910,719.04. Following the sale, the executive vice president now directly owns 5,334 shares of the company’s stock, valued at $1,200,043.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Timothy M. Ring sold 176 shares of Becton Dickinson and stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $218.27, for a total value of $38,415.52. Following the completion of the sale, the director now directly owns 170,688 shares in the company, valued at $37,256,069.76. The disclosure for this sale can be found here. Insiders sold 281,108 shares of company stock worth $61,321,396 over the last ninety days. Corporate insiders own 1.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3301409/envestnet-asset-management-inc-sells-336-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Intuit  Reaches New 1-Year High and Low at $182.93
Intuit Reaches New 1-Year High and Low at $182.93
Mitel Networks  Hits New 12-Month High and Low at $11.31
Mitel Networks Hits New 12-Month High and Low at $11.31
SodaStream  Reaches New 12-Month High and Low at $98.26
SodaStream Reaches New 12-Month High and Low at $98.26
$262.66 Million in Sales Expected for Voya Financial  This Quarter
$262.66 Million in Sales Expected for Voya Financial This Quarter
Zacks: Analysts Expect ICF  Will Post Quarterly Sales of $304.14 Million
Zacks: Analysts Expect ICF Will Post Quarterly Sales of $304.14 Million
American Ecology Co.  Expected to Post Quarterly Sales of $114.50 Million
American Ecology Co. Expected to Post Quarterly Sales of $114.50 Million


© 2006-2018 Ticker Report. Google+.